|
1.
|
Warshaw AL and Fernandez-del Castillo C:
Pancreatic carcinoma. N Engl J Med. 326:455–465. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
3.
|
Neoptolemos JP, Stocken DD, Friess H, et
al: A randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sener SF, Fremgen A, Menck HR and
Winchester DP: Pancreatic cancer: a report of treatment and
survival trends for 100,313 patients diagnosed from 1985–1995,
using the National Cancer Database. J Am Coll Surg. 189:1–7.
1999.PubMed/NCBI
|
|
5.
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
6.
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
|
|
7.
|
Akita H, Zheng Z, Takeda Y, et al:
Significance of RRM1 and ERCC1 expression in resectable pancreatic
adenocarcinoma. Oncogene. 28:2903–2909. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Nakahira S, Nakamori S, Tsujie M, et al:
Involvement of ribo-nucleotide reductase M1 subunit overexpression
in gemcitabine resistance of human pancreatic cancer. Int J Cancer.
120:1355–1363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Calin GA and Croce CM: MicroRNA-cancer
connection: the beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Croce CM and Calin GA: miRNAs, cancer and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Kapinas K, Kessler C, Ricks T, Gronowicz G
and Delany AM: miR-29 modulates Wnt signaling in human osteoblasts
through a positive feedback loop. J Biol Chem. 285:25221–25231.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Schmittgen TD, Jiang J, Liu Q and Yang L:
A high-throughput method to monitor the expression of microRNA
precursors. Nucleic Acids Res. 32:e432004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Tomimaru Y, Eguchi H, Nagano H, et al:
MicroRNA-21 induces resistance to the anti-tumor effect of
interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J
Cancer. 103:1617–1626. 2010.PubMed/NCBI
|
|
16.
|
Noda T, Nagano H, Takemasa I, et al:
Activation of Wnt/beta-catenin signalling pathway induces
chemoresistance to interferon-alpha/5-fluorouracil combination
therapy for hepato-cellular carcinoma. Br J Cancer. 100:1647–1658.
2009. View Article : Google Scholar
|
|
17.
|
Eguchi H, Nagano H, Yamamoto H, et al:
Augmentation of antitumor activity of 5-fluorouracil by interferon
alpha is associated with up-regulation of p27Kip1 in human
hepatocellular carcinoma cells. Clin Cancer Res. 6:2881–2890.
2000.PubMed/NCBI
|
|
18.
|
Jamieson CH, Ailles LE, Dylla SJ, et al:
Granulocyte-macrophage progenitors as candidate leukemic stem cells
in blast-crisis CML. N Engl J Med. 351:657–667. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Klaus A and Birchmeier W: Wnt signalling
and its impact on development and cancer. Nat Rev Cancer.
8:387–398. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Pasca di Magliano M, Biankin AV, Heiser
PW, et al: Common activation of canonical Wnt signaling in
pancreatic adenocarcinoma. PLoS One. 2:e11552007.PubMed/NCBI
|
|
21.
|
Zeng G, Germinaro M, Micsenyi A, et al:
Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
Neoplasia. 8:279–289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Barker N and Clevers H: Mining the Wnt
pathway for cancer therapeutics. Nat Rev Drug Discov. 5:997–1014.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Yang W, Yan HX, Chen L, et al:
Wnt/beta-catenin signaling contributes to activation of normal and
tumorigenic liver progenitor cells. Cancer Res. 68:4287–4295. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Su HY, Lai HC, Lin YW, et al: Epigenetic
silencing of SFRP5 is related to malignant phenotype and
chemoresistance of ovarian cancer through Wnt signaling pathway.
Int J Cancer. 127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Flahaut M, Meier R, Coulon A, et al: The
Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through
activation of the Wnt/beta-catenin pathway. Oncogene. 28:2245–2256.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Giovannetti E, Funel N, Peters GJ, et al:
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome
and pharmacologic aspects underlying its role in the modulation of
gemcitabine activity. Cancer Res. 70:4528–4538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Ali S, Ahmad A, Banerjee S, et al:
Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or
its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar
|
|
28.
|
Xiong Y, Fang JH, Yun JP, et al: Effects
of microRNA-29 on apoptosis, tumorigenicity and prognosis of
hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
29.
|
Fabbri M, Ivan M, Cimmino A, Negrini M and
Calin GA: Regulatory mechanisms of microRNAs involvement in cancer.
Expert Opin Biol Ther. 7:1009–1019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Gebeshuber CA, Zatloukal K and Martinez J:
miR-29a suppresses tristetraprolin, which is a regulator of
epithelial polarity and metastasis. EMBO Rep. 10:400–405. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Han YC, Park CY, Bhagat G, et al:
microRNA-29a induces aberrant self-renewal capacity in
hematopoietic progenitors, biased myeloid development and acute
myeloid leukemia. J Exp Med. 207:475–489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Resnick KE, Alder H, Hagan JP, Richardson
DL, Croce CM and Cohn DE: The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel
real-time PCR platform. Gynecol Oncol. 112:55–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
